Inflammatory disorders

FDA approves Wezlana for multiple inflammatory diseases

The U.S. Food and Drug Administration has approved Amgen's Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases.

page 4 from 40